Document:

Mutual Termination Agreement

 Exhibit 10.119 
 MUTUAL TERMINATION AGREEMENT 
 This Mutual Termination Agreement (this
“Agreement”) is dated October 25, 2006 (the “Effective Date” hereof) by and among Ryan Pharmaceuticals, Inc. a Delaware limited liability company (“Ryan”), Accentia, Inc., a Florida corporation
(“Accentia”), and TEAMM Pharmaceuticals, Inc., a Florida corporation (“TEAMM”). 
 WHEREAS, Ryan, Accentia and
TEAMM entered into a Distribution Agreement dated May 23, 2003 (the “Distribution Agreement”) pertaining to a 10/300 hydrocodone/acetaminophen Product (the 10/300 Product), as such Distribution Agreement has been amended by the
parties from time to time; 
 WHEREAS, Ryan, Accentia and TEAMM have mutually agreed to delete the 10/300 Product from the
Distribution Agreement as amended and to otherwise terminate the Distribution Agreement as amended except as set forth herein. 
 NOW,
THEREFORE, pursuant to Section 12.4 of the Distribution Agreement, Ryan, Accentia and TEAMM, for good and valuable consideration, including, without limitation, the elimination of the obligation of Accentia and TEAMM to make certain future
payments as set forth in Section 8 of the Distribution Agreement, and the obligation of Accentia and TEAMM to make a certain payment to Ryan as set forth in the Letter Agreement dated October 4, 2006 (and take certain other actions as set
forth therein), as such Letter Agreement has been amended and supplemented by the Amendatory and Supplemental Letter Agreement dated October 12, 2006, and for other good and valuable consideration, the receipt, adequacy and sufficiency of which
are hereby acknowledged, do hereby agree as follows: 
 1. Capital terms used herein that are not otherwise defined shall have the
meanings as given to them in the Distribution Agreement as amended. 
 2. The 10/300 Product is hereby deleted from the Distribution
Agreement, and the Distribution Agreement as amended is terminated except as set forth herein below, as of the Effective Date. For the avoidance of doubt, the effect of this termination is that all rights to “sell” (as that word is defined
in Section 3.1 of the Distribution Agreement) the 10/300 Product previously granted by Ryan to Accentia and TEAMM are being returned to and vested in Ryan, without any residual rights of any kind remaining with Accentia and TEAMM.

 3. Notwithstanding the termination of the Distribution Agreement as amended as set forth in Section 2 hereof, the provisions
thereof that survive termination, including those pertaining to product warranty and limitation of liability, confidentiality, indemnification and Section 11.3, shall remain in full force and effect in accordance with the terms and conditions
thereof as set forth in the Distribution Agreement as amended. 
 4. This Agreement shall be governed and interpreted, and all rights
and obligations of the parties shall be determined, in accordance with the laws of the State of California, without regard to its conflict of laws rules. All disputes with respect to this 

  

 1 

 
Agreement, which cannot be resolved by good faith negotiation among the parties, shall be brought and heard either in the California State Courts located
in Santa Clara County or the United States District Court for the Northern District of California located in San Jose, California. The parties to this Agreement each consent to the in personam jurisdiction and venue of such courts. The parties agree
that service of process upon them in any such action may be made if delivered in person, by courier service, by facsimile or by certified mail, postage prepaid, return receipt requested, and shall be deemed effectively given upon confirmed receipt
thereof. 
 5. This Agreement may be executed in two or three counterparts and any party hereto may execute any such counterpart, all
of which when executed and delivered shall be deemed to be an original and to which all counterparts, when fully executed by all of the parties, taken together shall constitute but one (1) and the same instrument. It shall not be necessary in
making proof of this Agreement or any counterpart hereof to account for any other counterpart except to the extent to show that another party signed and delivered the counterpart under which it is asserted to have certain responsibilities or
obligations. 
 6. The Agreement states the entire agreement among the parties hereto about the deletion of the 10/300 Product from,
and the termination of, the Distribution Agreement as amended, and supersedes all and all prior agreements, commitments, communications, negotiations, offers (whether in writing or oral), representations, statements, understandings and writings
pertaining thereto, and may not be amended or modified except by written instrument duly executed and delivered by all of the parties hereto. 
 IN WITNESS WHEREOF, this Mutual Termination Agreement has been duly executed and delivered by their duly authorized representatives to be effective as of the Effective Date. 
  

			
	Ryan Pharmaceuticals, Inc.
		
	By:	 	 /s/  Patricia Ryan

		 	Patricia Ryan
		 	President
	Date:	 	October 25, 2006
	
	Accentia Biopharmaceuticals, Inc.
	
	 /s/  Alan Pearce
  
 Alan Pearce

	Chief Financial Officer
	Date: October 25, 2006
	
	TEAMM Pharmaceuticals, Inc.
		
	By:	 	 /s/  Nicholas J. Leb

		 	Nicholas J. Leb
		 	Vice President, Finance
		 	Date: October 25, 2006

  

	
	xc: Hutchison & Mason PLLC
	3110 Edwards Mill Road, Suite 100
	Raleigh, North Carolina 27612
	 Attn: J. Robert Taylor, III

  

 2Fifth Amendment to Distribution Agreement

 Exhibit 10.120 
 FIFTH AMENDMENT TO DISTRIBUTION AGREEMENT 
 This Fifth Amendment to Distribution Agreement
(this “Fifth Amendment”) is dated October 25, 2006 (the “Effective Date” hereof) by and among Argent Development Group, LLC, a California limited liability company (“Argent”), Accentia, Inc., a Florida corporation
(“Accentia”), and TEAMM Pharmaceuticals, Inc., a Florida corporation (“TEAMM”). 
 WHEREAS, Argent, Accentia and
TEAMM entered into a Distribution Agreement dated May 12, 2004 (the “Distribution Agreement”) pertaining to, among other things, a 7.5/300 hydrocodone and acetaminophen Product (the 7.5/300 Product) and a 5.0/300 hydrocodone and
acetaminophen Product (the 5.0/300 Product), as such Distribution Agreement has been amended by the parties from time to time; 
 WHEREAS, Argent, Accentia and TEAMM have agreed to delete the 7.5/300 Product, and the 5.0/300 Product from the Distribution Agreement. 
 NOW, THEREFORE, pursuant to Section 12.4 of the Distribution Agreement, Argent, Accentia and TEAMM, for good and valuable consideration, including, without limitation, the elimination of the obligation of
Accentia and TEAMM to make certain future payments as set forth in Section 8 of the Distribution Agreement (as amended), and the obligation of Accentia and TEAMM to make a certain payment to Argent as set forth in the Letter Agreement dated
October 4, 2006 (and take certain other actions as set forth therein), as such Letter Agreement has been amended by the Letter Agreements dated October 12, 2006, October 23, 2006 and October 24, 2006, and for other good and
valuable consideration, the receipt, adequacy and sufficiency of which are hereby acknowledged, do hereby agree as follows: 
 1.
Capital terms used herein that are not otherwise defined shall have the meanings as given to them in the Distribution Agreement (as amended). 
 2. The 7.5/300 Product and the 5.0/300 Product are hereby deleted from the Distribution Agreement as of the Effective Date. For the avoidance of doubt, the effect of these deletions is that all rights to “sell” (as that word is
defined in Section 3.1 of the Distribution Agreement) the 7.5/300 Product and the 5.0/300 Product as previously granted by Argent to Accentia and TEAMM in the Distribution Agreement (as amended) are being returned to and vested in Argent,
without any residual rights of any kind remaining with Accentia and TEAMM. 
 3. Except for the Product deletions set forth in
Section 2 hereof, the Distribution Agreement (as amended) shall otherwise remain in full force and effect. 
 4. This Fifth
Amendment shall be governed and interpreted, and all rights and obligations of the parties shall be determined, in accordance with the laws of the State of California, without regard to its conflict of laws rules. All disputes with respect to this
Fifth Amendment, which cannot be resolved by good faith negotiation among the parties, shall be brought and heard either in the California State Courts located in Santa Clara County 

 
or the United States District Court for the Northern District of California located in San Jose, California. The parties to this Fifth Amendment each
consent to the in personam jurisdiction and venue of such courts. The parties agree that service of process upon them in any such action may be made if delivered in person, by courier service, by facsimile or by certified mail, postage prepaid,
return receipt requested, and shall be deemed effectively given upon confirmed receipt thereof. 
 5. This Fifth Amendment may be
executed in two or three counterparts and any party hereto may execute any such counterpart, all of which when executed and delivered shall be deemed to be an original and to which all counterparts, when fully executed by all of the parties, taken
together shall constitute but one (1) and the same instrument. It shall not be necessary in making proof of this Fifth Amendment or any counterpart hereof to account for any other counterpart except to the extent to show that another party
signed and delivered the counterpart under which it is asserted to have certain responsibilities or obligations. 
 6. This Fifth
Amendment states the entire agreement among the parties hereto with regard to the deletion of 7.5/300 Product and the 5.0/300 Product from the Distribution Agreement, and supersedes all and all prior agreements, commitments, communications,
negotiations, offers (whether in writing or oral), representations, statements, understandings and writings pertaining to such deletions, and may not be amended or modified except by written instrument duly executed and delivered by all of the
parties hereto. 
 IN WITNESS WHEREOF, this Fifth Amendment to Distribution Agreement has been duly executed and delivered by the
parties their duly authorized representatives to be effective as of the Effective Date. 
  

			
	Argent Development Group, LLC
		
	By:	 	 /s/  Kenneth Greathouse

		 	Kenneth Greathouse
		 	President
	Date:	 	October 25, 2006
	
	Accentia Biopharmaceuticals, Inc.
		
	By:	 	 /s/  Alan Pearce

		 	Alan Pearce
		 	Chief Financial Officer
		 	Date: October 25, 2006
	
	TEAMM Pharmaceuticals, Inc.
		
	By:	 	 /s/  Nicholas J. Leb

		 	Nicholas J. Leb
		 	Vice President, Finance
		 	Date: October 25, 2006

  

	
	xc: Hutchison & Mason PLLC
	3110 Edwards Mill Road, Suite 100
	Raleigh, North Carolina 27612
	 Attn: J. Robert Taylor, III

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00115-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00115-of-00352.parquet"}]]